Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LabTurbo BiotechROCO:7725 41 EBITDA Margin % is 55.09% as of Jun. 2026, which is 10% below its 10-year median of 61.22. GuruFocus rates ROCO:7725 with a GF Score™ of 41/100 and a GF Value™ of NT$28.69 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 943 Biotechnology companies, LabTurbo Biotech ranks better than 68.19% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. LabTurbo Biotech's EBITDA for the
six
months ended in Jun. 2026 was NT$28.69 Mil. LabTurbo Biotech's Revenue for the
six
months ended in Jun. 2026 was NT$52.09 Mil. Therefore, LabTurbo Biotech's EBITDA margin for the quarter that ended in Jun. 2026 was 55.09%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
LabTurbo Biotech EBITDA Margin % Related Terms
LabTurbo Biotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for LabTurbo Biotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7725 vs VRTX, REGN, MRNA: EBITDA Margin % Comparison
For the Biotechnology subindustry, LabTurbo Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LabTurbo Biotech EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LabTurbo Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where LabTurbo Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LabTurbo Biotech (ROCO:7725) has a EBITDA Margin % of 55.09% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on LabTurbo Biotech and its competitors. This is 10% below median its historical median of 61.22. According to the industry distribution chart, LabTurbo Biotech ranks #300 out of 943 companies in the Biotechnology industry, placing it in the top 31.8%.
Is LabTurbo Biotech's EBITDA Margin % too high?
LabTurbo Biotech's current EBITDA Margin % of 55.09% is 10% below median its 10-year median of 61.22. Based on the distribution chart, LabTurbo Biotech ranks #300 out of 943 companies in the Biotechnology industry, which is above the industry midpoint. Overall, LabTurbo Biotech has a GF Score™ of 41/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LabTurbo Biotech's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, LabTurbo Biotech ranks #300 out of 943 companies for EBITDA Margin %. This puts LabTurbo Biotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on LabTurbo Biotech and its competitors. LabTurbo Biotech's current EBITDA Margin % is 55.09%, which is 10% below median its own 10-year median of 61.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LabTurbo Biotech stock overvalued right now?
Based on GuruFocus' analysis, LabTurbo Biotech (ROCO:7725) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$28.69, compared to a current price of NT$22.30 — trading 22.3% below its estimated fair value. The current EBITDA Margin % is 55.09%, which is 10% below median its 10-year median of 61.22. LabTurbo Biotech's overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For LabTurbo Biotech (ROCO:7725), the current EBITDA Margin % is 55.09% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LabTurbo Biotech (ROCO:7725) Overvalued in 2026?
Based on GuruFocus' analysis, LabTurbo Biotech stock appears to be undervalued.
The current stock price of NT$22.30 is trading 22.3% below its estimated GF Value™ of NT$28.69.
GuruFocus considers LabTurbo Biotech to be Modestly Undervalued.
Key valuation signals for ROCO:7725:
EBITDA Margin %: 55.09% (10% below median its 10-year median of 61.22)
GF Value™: NT$28.69 vs. price of NT$22.30 (22.3% below fair value)
No single metric tells the full story. See the ROCO:7725 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LabTurbo Biotech Corp is a company that is mainly engaged in the research and development, production, sales of nucleic acid extraction, genetic testing, genetic testing reagents, instruments, and the operation of sports science venues. Its main products and services include the entire process. Automated precision medical genetic testing systems and reagent kits as well as testing services.
41GF Score
Get the complete analysis for ROCO:7725
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7725 has been successfully added to your 
